Product logins

Find logins to all Clarivate products below.


Drugs to Watch 2026

11 therapeutics worth the wait

For Drugs to Watch 2026, our team of analysts systematically selected eleven therapeutics that are likely to transform treatment paradigms and/or become blockbusters in the next five years. We provide an overview of our methodology and summaries of the selected drugs on this site. Our in-depth analysis and drug descriptions are available in the downloadable full report.

This year’s Drugs to Watch include next-generation GLP-1 drugs for weight loss and type 2 diabetes mellitus (T2DM), targeted protein degraders for cancer, precision medicines for rare diseases and new therapies in women’s health.

Download the Drugs to Watch 2026 report

2026 Drugs to Watch

Explore detailed summaries and analyst commentary on each drug

How we identified the Drugs to Watch

Since 2013, our annual Drugs to Watch report has relied on our proprietary technologies, tools and techniques that are also trusted by our global life sciences customers.

To identify the Drugs to Watch 2026 list, we drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs and markets and 10 integrated, AI-enhanced data sets that span the R&D and commercialization lifecycle. For the first time this year, we validated our findings using AI platforms and grouped the drugs by industry-relevant trends.